In Section C, members will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will receive treatment till condition progression or perhaps the individuals are not able to tolerate the study drugs. - "Our study discovered the vital purpose in the KLF16/MYC regulatory axis https://franciscos999fqb1.dm-blog.com/profile